These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22665482)

  • 21. Increased lipogenesis in cancer cells: new players, novel targets.
    Swinnen JV; Brusselmans K; Verhoeven G
    Curr Opin Clin Nutr Metab Care; 2006 Jul; 9(4):358-65. PubMed ID: 16778563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells.
    Gardner JA; Ha JH; Jayaraman M; Dhanasekaran DN
    Pancreas; 2013 Jul; 42(5):819-28. PubMed ID: 23508014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
    Jeong KJ; Park SY; Seo JH; Lee KB; Choi WS; Han JW; Kang JK; Park CG; Kim YK; Lee HY
    Exp Mol Med; 2008 Dec; 40(6):607-16. PubMed ID: 19116446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
    Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
    Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
    Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
    J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
    Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
    Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
    Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
    Chou CH; Wei LH; Kuo ML; Huang YJ; Lai KP; Chen CA; Hsieh CY
    Carcinogenesis; 2005 Jan; 26(1):45-52. PubMed ID: 15471896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
    Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
    Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
    Lin ME; Rivera RR; Chun J
    J Biol Chem; 2012 May; 287(21):17608-17617. PubMed ID: 22461625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
    Symowicz J; Adley BP; Woo MM; Auersperg N; Hudson LG; Stack MS
    Cancer Res; 2005 Mar; 65(6):2234-42. PubMed ID: 15781636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
    Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
    J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
    Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
    Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
    Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
    Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.
    Jeong BY; Cho KH; Yoon SH; Park CG; Park HW; Lee HY
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells.
    Do TV; Symowicz JC; Berman DM; Liotta LA; Petricoin EF; Stack MS; Fishman DA
    Mol Cancer Res; 2007 Feb; 5(2):121-31. PubMed ID: 17314270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
    Radhakrishnan R; Ha JH; Jayaraman M; Liu J; Moxley KM; Isidoro C; Sood AK; Song YS; Dhanasekaran DN
    Cancer Lett; 2019 Feb; 442():464-474. PubMed ID: 30503552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
    Tanyi J; Rigó J
    Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion.
    Lee M; Choi S; Halldén G; Yo SJ; Schichnes D; Aponte GW
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G641-54. PubMed ID: 19679818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.